Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioRestorative Therapies, Inc.

Market Cap 89.96L 77.53L 71.39L 67.03L 1.26Cr 85Cr 1.27Cr 8.44Cr 3.29Cr 42Cr 3.38Cr 3.3Cr 144.35Cr P/E Ratio 2026 *
-0.71x
P/E Ratio 2027 * -0.87x
Enterprise Value 89.96L 77.53L 71.39L 67.03L 1.26Cr 85Cr 1.27Cr 8.44Cr 3.29Cr 42Cr 3.38Cr 3.3Cr 144.35Cr EV / Sales 2026 *
6.4x
EV / Sales 2027 * 3.89x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day-9.69%
1 week-10.47%
Current month-26.13%
1 month+83.71%
3 months+22.65%
6 months-67.31%
Current year-69.95%
1 week 0.35
Extreme 0.3496
0.42
1 month 0.16
Extreme 0.1593
0.68
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
7.13
5 years 0.16
Extreme 0.1593
34.4
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2020
Director of Finance/CFO 59 04/11/2021
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 60 29/10/2021
Chairman 55 16/11/2020
Director/Board Member 37 12/06/2026
Date Insider Type Main position Quantity % Market Cap.
06/25/06Free

Chief Executive Officer

27,344 0.3427%
06/25/06Free

Chief Technology Officer

23,438 0.2938%
14/25/14Other

Chief Technology Officer

7,68,979 11.1125%
Change 5-day change 1-year change 3-year change Capi.($)
-9.69%-10.47%-78.20%-94.35% 89.96L
+0.79%-0.10%+61.21%+111.66% 5.45TCr
-1.22%+5.01%+43.38%+36.69% 4.39TCr
-1.43%+3.47%-15.83%-20.48% 2.26TCr
-1.99%-3.55%-5.97%+377.60% 2.07TCr
-0.67%+0.34%+15.95%-36.19% 1.58TCr
+1.72%-1.27%+10.17%-39.91% 1.48TCr
-1.70%-1.68%+24.79%+172.92% 1.31TCr
-5.17%+0.40%+21.68% - 1.27TCr
+0.29%+5.10%+75.82%+105.33% 1.16TCr
Average -1.91%+2.72%+15.30%+68.14% 2.1TCr
Weighted average by Cap. -0.73%+1.41%+31.65%+88.14%

Financials

2026 *2027 *
Net sales 14.05L 12.11L 11.15L 10.47L 19.65L 13Cr 19.86L 1.32Cr 51.33L 6.51Cr 52.73L 51.61L 23Cr 23.12L 19.93L 18.35L 17.23L 32.35L 22Cr 32.69L 2.17Cr 84.48L 11Cr 86.79L 84.94L 37Cr
Net income -1.35Cr -1.17Cr -1.07Cr -1.01Cr -1.89Cr -127.86Cr -1.91Cr -13Cr -4.94Cr -63Cr -5.08Cr -4.97Cr -216.99Cr -1.56Cr -1.34Cr -1.23Cr -1.16Cr -2.18Cr -147.1Cr -2.2Cr -15Cr -5.68Cr -72Cr -5.84Cr -5.71Cr -249.64Cr
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
16/26/16 0.3531 $ -9.69% 7,78,249
15/26/15 0.3910 $ +10.92% 12,72,087
12/26/12 0.3525 $ -6.25% 8,28,147
11/26/11 0.3760 $ -1.05% 4,39,162
10/26/10 0.3800 $ -3.65% 5,44,083
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3531USD
Average target price
8.000USD
Spread / Average Target
+2,165.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!